[Influence of pharmacological treatment on selected parameters of intrahepatic cholestasis of pregnancy].
Intrahepatic cholestasis occurs most frequently in the third trimester of pregnancy. It is characterized by elevated concentrations of liver enzymes and bile acids. The main aim of the study was to analyze the changes of concentration in biochemical indicators of cholestasis during the treatment.


METHODS
The study was conducted in the group of 38 women with diagnosed intrahepatic cholestasis in pregnancy and hospitalized in Medical University Lodz, High Risk Pregnancy Clinic in 2007-2008. Treatment constituted UDCA in 750 mg per 24h and Essentiale Forte 3 times a day. The concentrations in serum of AspAt, AlAt, ALP, GGTP, bile acids and bilirubin were estimated before and after 7 and 15 days of the treatment.


RESULTS
Mean concentration of AlAt was 262 +/- 16.26 U/L, AspAt 146 +/- 141.17 U/L, ALP 189 +/- 60.64 U/L, bile acids 28.6 +/- 15 micromol/L, GGTP 31.5 +/- 28.15 U/L but only in 28.9% was elevated. After 7 days the decrease of mean concentrations of AlAt (165 +/- 126.7 U/L) and AspAt (85 +/- 59.62 U/L) was observed. The concentration of ALP was similar to the previous results (190 +/- 71.94 U/L). After 15 days mean values of AlAt and AspAt decreased to 119 +/- 103.56 U/L and 65 +/- 46.12 U/L (p < 0.001), No changes in ALP concentration were found. The concentration of bile acids decreased after 15 days to 17 +/- 15 micromol/L.


CONCLUSIONS
The applied treatment decreased the concentration of most of biochemical markers of cholestasis. To reach the normal values of concentration of biochemical markers of cholestasis a 15-day treatment is necessary.
Brzozowska
Maria
M
Klinika Patologii Ciazy, I Katedra Ginekologii i Połoznictwa UM w Łodzi. agakar@interia.pl
Kowalska-Koprek
Urszula
U
Karowicz-Bilińska
Agata
A
D000328:Adult; D001647:Bile Acids and Salts / Q000097:blood*; D002756:Cholagogues and Choleretics / Q000008:administration & dosage*; D002780:Cholestasis, Intrahepatic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D003402:Creatine Kinase / Q000097:blood; D003907:Dexamethasone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D011044:Poland; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D011263:Pregnancy Trimester, Third / Q000097:blood; D018566:Pregnancy, High-Risk; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*; D055815:Young Adult; D005723:gamma-Glutamyltransferase / Q000097:blood
D001647:Bile Acids and Salts; D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid; D003907:Dexamethasone; D007770:L-Lactate Dehydrogenase; D005723:gamma-Glutamyltransferase; D003402:Creatine Kinase
Wpływ leczenia farmakologicznego na wybrane wykładniki cholestazy ciezarnych.